RecruitingRecruiting
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
NCT07223411 · University of Pittsburgh
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Dose-response Analysis of Nivolumab/Relatlimab in the Fixed-dosed Combination 'Opdualag' vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood for Participants With Unresectable or Metastatic Melanoma: A Corollary Study of HCC 24-056 (NCT06246916)
About this study
Cutaneous melanoma is an aggressive skin cancer which, in the metastatic setting, has a historic 5-year survival rate of \<30%. In 2023, about 97,610 new cases of melanoma were estimated to occur in the US, with about 7,990 deaths. GLOBACON reported 324,635 cases of melanoma globally in 2020, which constituted about 1.7% of all cancers and 57,043 melanoma-associated deaths.
The parent trial of this corollary study is a randomized, open-label, multicenter phase 3 study comparing the anti-tumor activity of fixed-dose combination (FDC) of fianlimab + cemiplimab versus the FDC of relatlimab + nivolumab (referred to as Opdualag™) in participants with unresectable or metastatic melanoma (stage III-IV). This corollary study will explore the immunological response of CD8, CD4, and other immune cells in the blood and tumor microenvironment of patients in response to the provided treatments.
Eligibility criteria
Inclusion Criteria:
1. Study participants who meet inclusion criteria for the HCC 24-056 study will be eligible for this study.
2. Participants must be willing to provide additional samples beyond what is required of them in HCC 24-056. These include:
1. 3 additional tumor biopsies
2. 3 additional blood draws
3. Participants must have biopsiable non-target disease amenable to at least 3 biopsies.
4. Must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
1\. Study participants who do not qualify to enroll in the HCC 24-056 study will not be eligible for this study.
\-
Study design
Enrollment target: 20 participants
Age groups: adult, older_adult
Timeline
Starts: 2025-11-19
Estimated completion: 2031-11-01
Last updated: 2026-11-19
Interventions
Drug: Fianlimab + CemiplimabDrug: Relatlimab + Nivolumab
Primary outcomes
- • Single-cell analysis of CD4+ T cells (Up to 39 months)
Sponsor
John Kirkwood · other
With: Regeneron Pharmaceuticals
Contacts & investigators
ContactDanielle L Bednarz, RN · contact · bednarzdl@upmc.edu · 4126231191
ContactAmy Rose, RN · contact · kennaj@upmc.edu · 4126478587
InvestigatorJohn M Kirkwood, MD · principal_investigator, UPMC Hillman Cancer Center
All locations (1)
UPMC Hillman Cancer CenterRecruiting
Pittsburgh, Pennsylvania, United States